Table 2 Utilities used for different health states in the model.

Well at age 30 with BRCA-1/2 mutation

0.92 (0.15)

Grann et al. 2010 [42]*

Breast cancer ^¶

pT1

0.68 (0.06)

Schleinitz et al., 2006 [43] ^§

pT2

0.61 (0.06)

Schleinitz et al., 2006 [43] ^§

pT3

0.56 (0.06)

Schleinitz et al., 2006 [43] ^§

pT4/ metastatic

0.42 (0.06)

Schleinitz et al., 2006 [43] ^§

Clinical remission (breast cancer survivors) ^†

0.83 (0.24)

Havrilesky et al., 2009 [44]

Ovarian cancer ^¶

FIGO I

0.81

Havrilesky et al., 2009; Kearns et al., 2016 [44, 45]*

FIGO II

0.72

Havrilesky et al., 2009; Kearns et al., 2016 [44, 45] *

FIGO III

0.63

Havrilesky et al., 2009; Kearns et al., 2016 [44, 45] *

FIGO IV/metastatic

0.55

Havrilesky et al., 2009; Kearns et al., 2016 [44, 45] *

Clinical remission (ovarian cancer survivors)

0.83 (0.25)

Havrilesky et al., 2009 [44]

Prophylactic surgeries

PBM

0.88 (0.24)

Grann et al., 2011 [33]*

PBSO

0.95 (0.24)

Grann et al., 2011 [33]*

PBM + PBSO

0.84 (0.25)

Grann et al., 2011 [33]*